ATE539163T1 - Auf der verwendung von mva beruhende impfstoffe - Google Patents
Auf der verwendung von mva beruhende impfstoffeInfo
- Publication number
- ATE539163T1 ATE539163T1 AT06703897T AT06703897T ATE539163T1 AT E539163 T1 ATE539163 T1 AT E539163T1 AT 06703897 T AT06703897 T AT 06703897T AT 06703897 T AT06703897 T AT 06703897T AT E539163 T1 ATE539163 T1 AT E539163T1
- Authority
- AT
- Austria
- Prior art keywords
- mva
- vaccines based
- present
- recombinant mva
- directed
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 230000005867 T cell response Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05001362A EP1683870A1 (de) | 2005-01-24 | 2005-01-24 | Auf die Verwendung von MVA basierte Impfstoffe |
PCT/EP2006/000608 WO2006077161A1 (en) | 2005-01-24 | 2006-01-24 | Vaccines based on the use of mv |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE539163T1 true ATE539163T1 (de) | 2012-01-15 |
Family
ID=34933432
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06703897T ATE539163T1 (de) | 2005-01-24 | 2006-01-24 | Auf der verwendung von mva beruhende impfstoffe |
Country Status (9)
Country | Link |
---|---|
US (1) | US20080075694A1 (de) |
EP (2) | EP1683870A1 (de) |
JP (2) | JP2008528457A (de) |
CN (1) | CN101142319B (de) |
AT (1) | ATE539163T1 (de) |
CA (1) | CA2595629A1 (de) |
DK (1) | DK1851320T3 (de) |
ES (1) | ES2380731T3 (de) |
WO (1) | WO2006077161A1 (de) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107735103B (zh) | 2015-02-25 | 2022-05-27 | 纪念斯隆-凯特琳癌症中心 | 使用灭活的非复制型的修饰的痘苗病毒安卡拉(mva)作为实体肿瘤的单一免疫疗法或与免疫检查点阻断剂的组合 |
CN116173193A (zh) | 2015-04-17 | 2023-05-30 | 纪念斯隆凯特琳癌症中心 | Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用 |
CN105039269A (zh) * | 2015-07-24 | 2015-11-11 | 北京鼎成肽源生物技术有限公司 | 一种用于治疗非小细胞肺癌的新型病毒疫苗及其制备方法 |
CN109071592B (zh) | 2016-01-08 | 2022-07-19 | 吉奥瓦科斯公司 | 用于产生对肿瘤相关抗原的免疫应答的组合物和方法 |
AU2017222686B2 (en) | 2016-02-25 | 2021-12-23 | Memorial Sloan Kettering Cancer Center | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy |
IL261321B2 (en) | 2016-02-25 | 2023-12-01 | Memorial Sloan Kettering Cancer Center | Recombinant MVA or MVADELE3L expressing human FLT3L and their use as immunotherapeutic agents against solid tumors |
WO2018032057A1 (en) * | 2016-08-19 | 2018-02-22 | Sementis Limited | Viral vaccines |
WO2018209315A1 (en) | 2017-05-12 | 2018-11-15 | Memorial Sloan Kettering Cancer Center | Vaccinia virus mutants useful for cancer immunotherapy |
WO2020176496A1 (en) | 2019-02-26 | 2020-09-03 | Maat Energy Company | Device and method for improving specific energy requirement of plasma pyrolyzing or reforming systems |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA68327C2 (en) * | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
WO2004093905A1 (en) * | 2003-04-16 | 2004-11-04 | City Of Hope | Human cytomegalovirus antigens expressed in mva and methods of use |
-
2005
- 2005-01-24 EP EP05001362A patent/EP1683870A1/de not_active Withdrawn
-
2006
- 2006-01-24 WO PCT/EP2006/000608 patent/WO2006077161A1/en active Application Filing
- 2006-01-24 DK DK06703897.6T patent/DK1851320T3/da active
- 2006-01-24 CA CA002595629A patent/CA2595629A1/en not_active Abandoned
- 2006-01-24 ES ES06703897T patent/ES2380731T3/es active Active
- 2006-01-24 JP JP2007551633A patent/JP2008528457A/ja active Pending
- 2006-01-24 CN CN2006800081604A patent/CN101142319B/zh not_active Expired - Fee Related
- 2006-01-24 EP EP06703897A patent/EP1851320B1/de not_active Not-in-force
- 2006-01-24 AT AT06703897T patent/ATE539163T1/de active
-
2007
- 2007-07-19 US US11/880,018 patent/US20080075694A1/en not_active Abandoned
-
2012
- 2012-07-17 JP JP2012158882A patent/JP2013014588A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
CN101142319B (zh) | 2012-05-23 |
CA2595629A1 (en) | 2006-07-27 |
CN101142319A (zh) | 2008-03-12 |
US20080075694A1 (en) | 2008-03-27 |
WO2006077161A1 (en) | 2006-07-27 |
EP1851320A1 (de) | 2007-11-07 |
ES2380731T3 (es) | 2012-05-17 |
EP1683870A1 (de) | 2006-07-26 |
DK1851320T3 (da) | 2012-04-16 |
JP2008528457A (ja) | 2008-07-31 |
EP1851320B1 (de) | 2011-12-28 |
JP2013014588A (ja) | 2013-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE539163T1 (de) | Auf der verwendung von mva beruhende impfstoffe | |
DE602006019050D1 (de) | Polypeptide mit cellobiohydrolaseaktivität und dafür kodierende polynukleotide | |
DK1831362T3 (da) | Syreaktive svampeproteaser | |
ATE513907T1 (de) | Polypeptide mit endoglucanase-aktivität und polynukleotide zu ihrer kodierung | |
EA201590545A1 (ru) | Полипептиды, содержащие fc с измененным гликозилированием и сниженной эффекторной функцией | |
NO20054792D0 (no) | Nukleinsyresekvenser som koder proteiner assosiert med abiotisk stressrespons og planteceller og planter med okt toleranse for miljobetinget stress | |
DK1578964T4 (da) | Polypeptider med cellobiohydrolase II-aktivitet og polynukleotider, der koder for samme | |
ATE515568T1 (de) | Polypeptide mit endoglucanase-aktivtät und dafür codierende polynukleotide | |
DK1976871T3 (da) | Vacciner og immunterapeutika under anvendelse af codonoptimerede IL-15 og fremgangsmåder til anvendelse deraf | |
DE60325892D1 (de) | Stellungs- und verwendungsverfahren | |
EA201491494A1 (ru) | Нацеливание на гликаны хондроитинсульфаты | |
EA200800174A1 (ru) | Резистентные к гербицидам растения подсолнечника, полинуклеотиды, кодирующие резистентные к гербицидам большие субъединицы белков ацетогидроксикислотной синтазы, и способы применения | |
ATE512980T1 (de) | Polypeptide mit beta-glucosidase-aktivität sowie diese codierende polynukleotide | |
ATE536425T1 (de) | Mit metabolischem alter verbundene biomarker und verfahren zur verwendung davon | |
DK1841874T3 (da) | Leadersekvenser til at lede secernering af polypeptider og fremgangsmåder til fremstilling heraf | |
CO6341638A2 (es) | Axmi-115, axmi-113, axmi-005, axmi-163 y axmi-184: proteinas insecticidas y metodos para su uso | |
ATE447013T1 (de) | Polypeptide mit endoglucanase-aktivtät und dafür codierende polynukleotide | |
ATE378426T1 (de) | Neue sequenz um die expression einer nukleinsäure zu erhöhen | |
ATE466874T1 (de) | Mit scytovirin der domäne 1 verwandte polypeptide | |
DK1756273T3 (da) | Signalpeptid til frembringelse af et polypeptid | |
DE602006008330D1 (de) | Verwendungsverfahren | |
ATE486127T1 (de) | Wiederherstellung der aktivität von 5- enolpyruvylshikimat-3-phosphat-synthase durch fragmentkomplementierung | |
ATE456797T1 (de) | Verwendung von nogo-c bei der beurteilung von herzversagen | |
DK1630232T3 (da) | Optimerede nukleotidsekvenser kodende for sgp130 | |
ATE518003T1 (de) | Verfahren zur identifizierung von cd4+-t-zellen- antigenen |